at Zacks.com (Fri, 8:40AM)
Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III...
Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III clinical trial using Ibrutinib versus Chlorambucil to treat chronic lymphocytic leukemia and small lymphocyctic lymphoma has enrolled its fifth patient. The enrollment subsequently triggers a fourth $50M milestone payment obligation from JNJ's Janssen Biotech, who is collaborating with PCYC on Ibrutinib in oncology. On Monday, the drug was granted a 3rd "Breakthrough Therapy Designation" by the FDA.
From other sites
at Zacks.com (Jan 20, 2015)
at Zacks.com (Jan 16, 2015)
at Benzinga.com (Jan 15, 2015)
Pharmacyclics Inc. (PCYC): New Analyst Report from Zacks Equity Research - Zacks Equity Research Reportat Zacks.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs